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Abstract
Background When used for a therapeutic purpose such as
for psychiatric illness, psychotropic drugs may enhance
quality of life; however, when used to treat behaviours
associated with dementia, they may have only a modest
effect but lead to negative outcomes.
Objective We undertook an analysis of community-
dwelling people with dementia or cognitive impairment to
ascertain how prolific psychotropic medicine use is within
the Australian community setting, which psychotropic
medicines are being prescribed and to whom, and whether
the use of such medicines is in accordance with therapeutic
guidelines.
Methods We undertook a retrospective review of medi-
cation records, including medication charts, for 412 people
with cognitive impairment, discharged from a home nurs-
ing service in Victoria, Australia, during the 6-month
period between 1 January and 30 June 2013.
Results Cholinesterase inhibitor use exceeded the number
of individuals with a recorded diagnosis of Alzheimer’s
disease; in some cases, the dosage exceeded recommen-
dations. Antidepressants were used by more than double
the number of people documented with a history of
depression. Antipsychotic medicines were prescribed for
undocumented purposes, in some cases above maximum
response levels, and multiple benzodiazepines were
prescribed.
Conclusions Psychotropic medicine use was common in
our study population, and use of these medicines was often
not in line with therapeutic guidelines. Further research is
required to ascertain reasons for the high use of psy-
chotropic medicines in this group, and greater considera-
tion is required by health professionals of the appropriate
use and regular review of psychotropic medicines.
Improved documentation of diagnoses and the indications
for prescribing psychotropic medicines is needed, as is
greater implementation of educational programmes to
support care workers and carers.
Key Points
Use of psychotropic medications was high in people
with dementia living in the community, and further
research needs to be undertaken to understand why.
Greater consideration by health professionals of
appropriate use and regular review of psychotropic
medicines is required.
Improved documentation of the indications for
prescribing psychotropic medicines is required.
There is a need for greater implementation of
educational programmes to support care workers and
carers of people with dementia living in the
community setting.
1 Background
Psychotropic drugs are medicines that impact on mental
functioning and may alter cognition, emotions and beha-
viour. The word psychotropic originates from the Greek
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term ‘psycho’, referring to ‘the mind’, and ‘tropic’, refer-
ring to ‘turning’. Psychotropic drugs may be used in either
a positive or a negative manner. When used for a thera-
peutic purpose such as for the treatment of psychiatric
illness, these drugs may enhance quality of life; however,
when used to treat behaviours associated with dementia,
they have been shown to have only a modest effect and
may lead to many negative outcomes [1].
Psychotropic medicines include the following: antipsy-
chotics—medicines used to treat psychotic disorders;
antidepressants—medicines used to treat depression and
anxiety disorders; anxiolytics—medicines used to treat
anxiety disorders; hypnotics—used to treat insomnia; mood
stabilisers—used to treat bipolar disorders; and cholines-
terase inhibitors—used as cognition-enhancing agents in
Alzhiemer’s disease [2]. More specifically, antipsychotic
medicines, benzodiazepines and antidepressants became
available in the 1950s as a treatment for schizophrenia,
psychosis, paranoid delusions, abnormal thoughts or
behavioural disorders and depression. However, since the
late 1980 s, there has been a steady stream of new agents
introduced to treat depression, anxiety, insomnia and neu-
ropsychiatric and behavioural disturbances [2].
Behavioural and psychological symptoms of dementia
(BPSD), including agitation and aggression, are increas-
ingly recognised as a major risk factor for caregiver stress
and institutionalisation of people with dementia [3–5]. The
use of psychotropic drugs to control BPSD in older people
with dementia is widespread, both in Australia [6] and
internationally [7, 8]. Treatment of BPSD using psy-
chopharmacological approaches, especially antipsychotics,
is problematic, as exposure to anticholinergic and sedative
medications is associated with functional impairment in
older people; additionally, the use of antipsychotic
medicines in older people frequently leads to adverse
effects, including the risk of cerebrovascular events (in-
creased risk of stroke), extrapyramidal side effects, tardive
dyskinesia (movement disorders) and mortality [9]. Con-
sequently, the use of antipsychotic medicine to control
BPSD in older people with dementia has become contro-
versial [5, 10–13].
A recent study of Scottish nursing homes reported that
three-quarters of all residents received at least one
antipsychotic medicine to manage behavioural symptoms,
and over 70 % of 1715 people admitted to aged care homes
during this study commenced the medication prior to their
admission [14]. Rattinger et al. [15] similarly reported a
high use of psychotropic medicines in older people with
dementia, both in residential care facilities and in those
living in the community in the USA. Currently, in Australia
there is also evidence of an increase in the prescribing of
psychotropic medicines for older people living in aged care
homes [6, 16–18]. This apparent preference for
pharmaceutical management rather than behavioural ther-
apy to control BPSD in older people is concerning [3] and
recently led to the Australian Federal Government estab-
lishing a Senate Inquiry on ‘the care and management of
younger and older Australians living with dementia and
behavioural and psychiatric symptoms of dementia’ [19].
There is anecdotal evidence of the use of psychotropic
medicines in older people living in the community; how-
ever, the extent of the use and/or appropriateness remains
unknown [20]. We undertook a retrospective analysis of
psychotropic medicine use by people receiving support
from a home care nursing service provider who were
documented as having a diagnosis of dementia, Alzhei-
mer’s disease, cognitive impairment or short-term memory
loss to establish how prolific is the use of psychotropic
medicines in older people with cognitive impairment living
within the community setting, which psychotropic
medicines are being prescribed, and for what reasons are
these medicines being prescribed?
2 Methods
2.1 Study Design
We retrospectively reviewed the medical records of people
receiving support from a home care nursing service pro-
vider in Victoria, Australia.
2.2 Participants
Participants were clients who were documented as having a
diagnosis of either Alzheimer’s disease, dementia, short-
term memory loss or cognitive impairment and were dis-
charged from the home care nursing service provider
between 1 January and 30 June 2013.
2.3 Data Collection
A list of the 412 older people identified as having a diag-
nosis of dementia, cognitive impairment or short-term
memory loss (including Alzheimer’s, vascular dementia)
who were discharged during the study period was produced
from the home care nursing service database. Medical
records for this group were retrieved, and those found to
have been prescribed psychotropic medicines were further
examined to ascertain the reason psychotropic medicine
was prescribed, as well as the reason for discharge. Data
were collected using a pre-piloted audit form developed by
the research team, which included an expert consultant
pharmacist. The audit form collected information on par-
ticipant’s age and sex, diagnoses of cognitive impairment
and use of psychotropic medicines, including active
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ingredient, dose and timing of the dose. Data collected on
the use of psychotropic medicines were reviewed by both a
practising and a research pharmacist to ascertain whether
the indication for use of these medicines coincided with
current clinical guidelines (i.e. prescribed in accordance
with therapeutic guidelines for older people’s diagnosis as
documented in the medical record) [13].
2.4 Outcome Measures/Study Endpoints
2.4.1 Primary
The primary outcome measure was the prevalence of the
use of psychotropic medicines among the study population;
and those who had no history of a mental illness or
apparent therapeutic reason for use of a psychotropic
medicine [13].
2.4.2 Secondary
The secondary outcome measure was the medication use
pattern for each class of psychotropic medicines among the
study population (number of psychotropic medicines pre-
scribed and dosage).
2.5 Data Analysis
Data were entered into the Statistical Package for Social
Sciences (SPSS) version 21 (IBM, Armonk, NY, USA) for
descriptive analysis. Categorical variables were presented
as frequency and proportion, and continuous variables were
presented as mean and standard deviation (SD) for non-
skewed data, or median and interquartile range (IQR) for
skewed data.
3 Results
A total of 412 people documented as having a diagnosis of
Alzheimer’s disease, dementia, short-term memory loss or
cognitive impairment were discharged from the home care
nursing service provider during the 6-month study period.
Of these, 251 (61 %) were recorded as having been pre-
scribed one or more psychotropic medicines. Medical
records for 30 of the 251 people were unavailable at the
time of the audit, due to the person being re-admitted to the
home nursing service and their medical records being
located at their home. Therefore, our analysis focused on
the remaining 221 cases.
3.1 Characteristics of the Study Population
The mean age of the 221 people using psychotropic
medicines was 84 ± 7.7 years (range 43–98) with the
mode being 86 years of age (20 cases). A total of 45
individuals (20 %) were aged over 90 years, and 172
(78 %) were aged over 80 years. A higher number of those
identified as using psychotropic medicines were female:
148 women (67 %) had been prescribed a psychotropic
medicine compared with 77 (34.8 %) men.
Those identified as using psychotropic medicines had
been admitted to receive home nursing care from one of the
13 care provider sites. The percentage of those with a
diagnosis of dementia, Alzheimer’s, cognitive impairment
or short-term memory loss, who had been prescribed psy-
chotropic medicines from across the sites, ranged between
35 and 69 %. The highest percentage of those using psy-
chotropic medicines were receiving home nursing care in
the metropolitan areas of Caulfield (69 %), Diamond
Valley (62 %) and Heidelberg (62 %).
3.2 Cognition Screening
Of those identified as taking psychotropic medicines, 144
(65 %) had dementia screening details recorded. Of these,
128 had been screened using the Mini-Mental Status
Examination (MMSE) [21] and 16 using the Rowland
Universal Dementia Assessment Scale (RUDAS) [22]. The
remaining 77 (35 %) had no evidence of cognition
screening in their record.
3.3 Diagnosed with a Condition of Cognitive
Impairment and/or Mental Illness
Of the 221 individuals whose medical records were
checked for use of psychotropic medicines, 64 (29 %) had
a diagnosis of dementia and 66 (30 %) had Alzheimer’s
disease; 47 (21 %) had a diagnosis of cognitive impairment
and 44 (20 %) were diagnosed with short-term memory
loss.
Of those identified as having either dementia, Alzhei-
mer’s disease, cognitive impairment or short-term memory
loss who were using one or more psychotropic medicines,
54 (24 %) had a co-existing diagnosis of mental illness. Of
these, 38 were documented as having a diagnosis of
depression, five bi-polar affective disorder, one
schizophrenia and 22 anxiety (13 were documented as
having more than one mental illness). The remaining 167
(76 %) of those using psychotropic medicines had no co-
existing mental illness recorded.
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Table 1 Antidepressant drug indications, recommended daily dosage, number of clients using antidepressant medicines and prescribed dose
ranges
Antidepressants, indication and maximum recommended
dose according to indication
n = 103 (46.6 %) Prescribed dose as documented
in health record (range)
Amitriptyline
Depression: maximum dose 300 mg per day
Neuropathic pain: 150 mg per day
Migraine: 75 mg per day
Urge incontinence: 75 mg per day
11 (5.0) 10–50 mg at night
Citalopram (Maximum 40 mg per day)
Major depression
Anxiety disorders, e.g. panic disorder, OCD
Bulimia nervosa
Premenstrual dysphoric disorder
18 (8.1) 10–40 mg per day
Desvenlafaxine
Major depression: 200 mg per day
4 (1.8) 50–100 mg mornings
Duloxetine
Depression: 60 mg per day
Generalised anxiety disorder: 120 mg per day
Diabetic neuropathy: 60 mg per day
6 (2.7) 30–120 mg per day





21 (9.5) 10–20 mg per day usually mornings
Fluoxetine
Major depression: 60 mg
OCD: 80 mg
Premenstrual dysphoric disorder: 20 mg
2 (0.9) 20 mg morning
Fluvoxamine
Major depression: 300 mg
OCD: 300 mg per day
2 (0.9) 100–200 mg at night
Mirtazapine
Major depression: 60 mg per day
17 (7.7) 10–45 mg per day
Paroxetine
Depression: 50 mg
Generalised anxiety disorder: 20 mg
OCD/panic disorder: 50 mg per day
6 (2.7) 20 mg per day
Sertraline
Depression: 200 mg per day
OCD: 200 mg per day
Panic disorder: 50 mg per day
28 (12.7) 50–100 mg per day
Venlafaxine
Major depression: 225 mg
Generalised anxiety disorder: 225 mg
Panic disorder: 225 mg
Social phobia: 225 mg
9 (4.1) 75–300 mg per day
Using two or more antidepressants 5 (2.3)
Source: Australian Medicines Handbook 2015, http://www.amh.net.au
OCD obsessive compulsive disorder
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3.4 Prevalence of Psychotropic Medicine Usage
Although 126 (57 %) consumers were prescribed one psy-
chotropic medicine, the use of more than one psychotropic
medicine was not unusual. The number of prescribed psy-
chotropic medicines ranged between one and five. A total of
67 (30 %) consumers were receiving two psychotropic
medicines and 24 (11 %) were receiving three (median
number of psychotropic medicines 1.0; IQR 1–2).
3.5 Cholinesterase Inhibitors
In total, 91 persons had been prescribed cholinesterase
inhibitors, 64 (29 %) were prescribed donepezil, 18 (8 %)
were prescribed galantamine and nine (4.1 %) were pre-
scribed rivastigmine. Three people—two women aged 81
and 91 years and one male aged 95 years—who had been
prescribed rivastigmine were receiving doses above the
therapeutic range 18 lg. Two participants were co-pre-
scribed donepezil and memantine and galantamine and
memantine. Of those prescribed cholinesterase inhibitors, 51
(56.0 %) were documented as having a specific diagnosis of
Alzheimer’s disease and 27 (30 %) were documented as
having dementia. The remaining 12 (13 %) people were
recorded as having cognitive impairment or short-term
memory loss but no formal diagnosis of dementia.
3.6 Antidepressants
A total of 103 persons had been prescribed antidepres-
sant(s); 38 of them had a diagnosis of depression
Table 2 Antipsychotics, indication for use and recommended dosage, number of clients using antipsychotic medicines and prescribed dose
Antipsychotic, indication and recommended maximum dosage n = 39 (17.6 %) Prescribed dose as documented in
health record (range)
Haloperidol
Acute and chronic psychosis: 1–5 mg, 2–3 times per day
Acute mania in bipolar: 5–10 mg, 2 hourly when required
Not recommended for BPSD
Long-acting injection: 50–300 mg every 4 weeks
In elderly, use low doses: 0.5–10 mg/day
n = 4 (1.8) 0.5 mg per day
Olanzapine
Schizophrenia: 20 mg per day
Bipolar: 20 mg per day
BPSD: no listing
n = 5 (2.3) 1.25–2.5 mg at night (n = 4)
15 mg morning (n = 1)
Paliperidone
Schizophrenia: 25–150 mg once a month
BPSD: no listing
n = 1 (0.5) 75 mg monthly
Pericyazine
Schizophrenia: 30 mg per day
Not recommended for BPSD
n = 2 (0.9) 10 mg at night (n = 1)
2.5 mg three times per day
(n = 1)
Quetiapine
Schizophrenia: 800 mg per day
Bipolar: 800 mg per day
General anxiety disorder: 150 mg per day
Adjunct in depression: 300 mg per day
Not recommend for BPSD
n = 9 (4.1) 25 mg–600 mg per day
Risperidone
Schizophrenia and related psychoses: 4–6 mg per day
Bipolar disorder: 2–6 mg/day
BPSD: 0.25–2 mg per day after non-drug strategies have been unsuccessful
Conduct and other disruptive behaviour disorders in people with sub-average
intellectual functioning or mental retardation: 0.5–1.5 mg (lower doses if\50 kg
Behavioural disorders in autism: 0.5–2.5 mg per day
n = 18 (8.1) 0.5 mg (n = 12)
0.5 mg as needed (n = 1)
1 mg (n = 3)
3 mg (n = 1)
5 mg (n = 1)
Prescribed more than one antipsychotic n = 0
Source: Australian Medicines Handbook 2015, http://www.amh.net.au
BPSD Behavioural and psychological symptoms of dementia
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documented in their case record (see Table 1). Five persons
had been prescribed two antidepressants: amitriptyline
10 mg once daily in combination with either (1) mirtaza-
pine 30 mg once daily (n = 2); (2) escitalopram 10 mg/
20 mg once daily (n = 2); or (3) citalopram 10 mg once
daily (n = 1). None of these five cases had a diagnosis of
depression, insomnia or chronic neuropathic pain docu-
mented in their records.
Table 3 Benzodiazepines, indication for use and recommended dosage, number of clients using Benzodiazepines and prescribed dose range
Benzodiazepines
Indication and recommended dosage
n = 69 (31.2 %) Prescribed dose as documented
in person’s health record (range)
Alprazolam
Anxiety/panic disorder: 10 mg per day
5 (2.3) 0.25–3 mg per day
Clonazepam
Epilepsy: 8 mg per day
10 (4.5) 0.5–0.8 mg every 4 h
0.3–0.5 mg as needed
2–30 mg as needed/at night
Diazepam
Anxiety: 30 mg per day
Muscle spasm: 60 mg per day
13 (5.9) 2–5 mg per day
Nitrazepam
Hypnotic: 10 mg per day
2 (0.9) 5 mg per day
Oxazepam
Severe anxiety: 120 mg per day
Hypnotic: 30 mg per day
12 (5.4) 15–30 mg at night
Temazepam
Hypnotic: 20 mg per day
Lower doses recommended in elderly
25 (11.3) 10–20 mg at night/as needed
Midazolam
Palliative care: 2.5–5 mg hourly
2 (0.9) 1–2 mg every 2–4 h (n = 1)
2 mg intravenously as needed (n = 1)
Total 69 (31.2)
Source: Australian Medicines Handbook 2015, http://www.amh.net.au
Table 4 Number of clients using other psychotropic medicines
Indication and recommended dosage n = 23 (10.4 %) Prescribed dose as documented
in health record (range)
Memantine
Moderate to severe AD: 20 mg once daily
7 (3.2) 10–20 mg per day
Carbamazepine
Epilepsy: 2 g daily
Bipolar disorder: 1.6 g daily
Neuralgia: 1.2 g daily
4 (1.8) 100-300 mg twice a day
Lithium
Bipolar disorder: 2500 mg daily
2 (0.9) 250 mg twice a day
Sodium valproate
Epilepsy: 2500 mg daily
Bipolar disorder: 1000–2000 mg daily
9 (4.1) 100–1200 mg per day
Zolpidem
Insomnia: 10 mg daily (conventional tablet), 12.5 mg daily (controlled-release tablet)
1 (0.5) 10 mg at night
Using two or more other psychotropic medicines 12 (5.4)
Source: Australian Medicines Handbook 2015, http://www.amh.net.au
AD Alzheimer’s disease
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3.7 Antipsychotics
Antipsychotic medicines were prescribed to 39 persons
(see Table 2). Five had a diagnosis of bi-polar affective
disorder and one had a diagnosis of schizophrenia, which
were indications for a prescription of antipsychotics. The
most common antipsychotic prescribed, risperidone, was
prescribed for 18 persons, 15 of whom were aged over
80 years. Of the nine people prescribed quetiapine, seven
were aged 80 years or over.
3.8 Benzodiazepines
Benzodiazepines were prescribed for 69 (31.2 %) persons
in the study sample. The most common—temazepam—was
prescribed for 25 persons, 22 of whom were aged over
80 years (see Table 3). Ten persons (4.5 %) were pre-
scribed two or more benzodiazepines. These included
alprazolam, oxazepam and temazepam, alprazolam and
clonazepam, temazepam and midazolam, clonazepam and
midazolam, and diazepam and clonazepam.
3.9 Other Psychotropic Medicines
In our cohort of clients, use of other psychotropic
medicines such as memantine, carbamazepine, lithium,
sodium valproate and zolpidem was low (see Table 4).
3.10 Reasons for Discharge from Home Nursing
Service
Over 127 (57.5 %) of the people in our study were dis-
charged to short- or long-term institutional or residential
care services: 52 (23.5 %) to acute care, 47 (21.3 %) to
permanent or supported care and 28 (12.7 %) to respite
care. Persons (27 %) were discharged from home nursing
services due to problem resolution (16.7 %) or ability to
self-care (10.9 %). The remainder of the study population
(2.7 %) were discharged to palliative care services or
deceased.
4 Discussion
This study identified a high prevalence of psychotropic
medicine use in the study sample, with more than half of
those with a documented diagnosis of dementia, Alzhei-
mer’s disease, cognitive impairment or short-term memory
loss prescribed one or more psychotropic medicines. While
psychotropic medicine use in people with dementia or
memory problems ranged between 35 and 69 % across the
13 sites delivering home nursing services, use at more than
half of the sites exceeded 50 %; at three sites, the
percentage of those who had been prescribed psychotropic
medicines exceeded 60 %. This may reflect the prescribing
practices of health professionals in the various geographic
areas. As is the case in other studies, a higher number of
females than males had been prescribed psychotropic
medicine [7, 10]. This may partially be explained by the
higher proportion of older females in the overall population
[18].
Use of psychotropic medicines is a potential risk factor
for medication-related problems, adverse effects, hospital-
isations and increased risk of mortality [16, 23–34], and in
older people the use of antipsychotic medication is asso-
ciated with an increased risk of stroke and death, with the
risk being greatest early in the treatment and with higher
doses [15, 16, 23–34]. Therefore, the finding that 78 % of
those prescribed psychotropic medicines were aged over
80 years was unexpected. This is despite evidence of a link
between adverse outcomes from these medications and
increasing age [28–30]. Regardless of the potential adverse
effects, use of antidepressants, antipsychotics and benzo-
diazepines was high in the population we studied, and
prescribed cholinesterase inhibitors, indicated for those
with a diagnosis of Alzheimer’s disease, exceeded the
number of people with a formal diagnosis.
Cholinesterase inhibitors may only be prescribed on the
Australian Pharmaceutical Benefits Scheme (PBS) once a
set of criteria are met, including results of the MMSE (or
similar) with a score of\9, and a diagnosis of Alzheimer’s
disease confirmed with a specialist consultant physician
(including a psychiatrist). Although the use of cholines-
terase inhibitors in our population was low, two women
aged 81 and 91 years and one man aged 95 years, who had
been prescribed a cholinesterase inhibitor (rivastigmine)
were receiving doses above the therapeutic range (18 lg).
Additionally, 13 % of patients who had been prescribed a
cholinesterase inhibitor had no formal diagnosis of Alz-
heimer’s disease recorded in their medical records.
A total of 103 persons had been prescribed antidepres-
sant(s), but only 38 had a diagnosis of depression docu-
mented in their medical record. The most common
antidepressants prescribed to older people in our sample
were selective serotonin re-uptake inhibitors such as
Cipramil (citalopram), Zoloft (sertraline) and Lexapro
(escitalopram). Use of mirtazapine, a noradrenaline and
specific serotonin agonist was also common. Although all
doses of antidepressants were within ranges recommended
in the Australian Medicines Handbook therapeutic guide-
lines, five persons who had been prescribed antidepres-
sant(s) were at risk of potential drug interactions (serotonin
syndrome) from using two antidepressants.
Antipsychotics were prescribed to 39 persons; however,
only five were documented as having a history of bi-polar
affective disorder and one of schizophrenia, indications for
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the prescription of antipsychotics. More specifically,
haloperidol, olanzapine, paliperidone, pericyazine and
quetiapine are indicated for use in schizophrenia and
bipolar affective disorder; however, these medicines were
prescribed to 21 persons without these diagnoses. This
raises the possibility that the use of these antipsychotics in
15 cases may have been for purposes other than thera-
peutic, particularly BPSD. For example, in Australia,
quetiapine is not registered for treating BPSD; however,
nine clients were prescribed quetiapine, only six of whom
had a condition for which quetiapine is indicated. Equally
concerning was that although risperidone, the most com-
monly prescribed antipsychotic in our study, is licensed for
use in BPSD, in some cases it was prescribed above the
therapeutic range [13]. Despite being less well tolerated in
older people, the doses of risperidone prescribed for the
study sample ranged between 0.5 and 5 mg per day.
Although recommendations from the Australian Thera-
peutic Guidelines cite risperidone 5 mg for treatment of
schizophrenia, doses above 2 mg per day in people with
dementia do not lead to an increased response in BPSD
[13]. In one case it was documented that the introduction of
haloperidol had commenced during a respite placement,
and a note on the medication chart directed that it be
continued after returning home.
Antipsychotic use is associated with a number of
adverse effects, including sedation, exacerbation of exist-
ing cognitive impairment and confusion, falls with subse-
quent fractures, urinary tract infections, gait disturbances,
increased risk of diabetes, and peripheral oedema. Anti-
cholinergic side effects are also common and include
delirium, constipation, xerostomia, urinary retention and
blurred vision. Extrapyramidal side effects, including
akathisia, dystonia, parkinsonism and tardive dyskinesia
(abnormal movements of the tongue), can also occur.
Whilst all antipsychotics can cause extrapyramidal side
effects, they are more common in higher doses and with
conventional agents such as haloperidol [23–34]. Studies
have also demonstrated an increased risk of stroke and
mortality when antipsychotics are used in older people with
dementia [23, 24, 27].
Benzodiazepines are frequently used to treat anxiety and
sleeping disorders. All guidelines recommend only short-
term use of up to 2–4 weeks due to the risk of tolerance and
dependence developing and the risk of adverse effects such
as increased falls and confusion. In our study sample,
benzodiazepines were used by more than double the
number of people who had a documented diagnosis of
anxiety. Clonazepam is often used as a palliative care
treatment; however, while it is likely this may be the
indication for use of this drug in some cases, it does not
explain fully the use of this medicine as the reason given
for discharge in the study period indicated that only a small
number of discharges from home nursing care were for
palliative care or due to the death of the care recipient. A
majority of the study population discharged from home
nursing care were transferred to either acute care, perma-
nent care or to respite care facilities. As institutionalisation
has been attributed to caregiver burden resulting from
BPSD [1–4], a possible explanation for the high use of
psychotropic medicines in our study population may have
been associated with managing agitation and/or aggression.
Benzodiazepines (hypnotics and anxiolytics) are also
frequently used to manage sleep disturbance and anxiety
problems despite no benefit in their long-term use as the
effect diminishes with prolonged use [12].
Similarly to other psychotropic medicines, side effects
in older people are common due to age-related physio-
logical changes such as receptors in the brain becoming
more sensitive to the benzodiazepines and leading to slo-
wed reflexes, changes in absorption, metabolism, elimina-
tion, muscle mass, impaired motor and visual co-
ordination, impaired cognition and confusion [12].
Our findings add support to two recently published
studies. Marston et al. [35] concluded that less than half of
the people prescribed first-generation antipsychotics in the
UK had a diagnosis of psychosis or bipolar disorder, and
antipsychotic agents were more commonly prescribed to
older people despite the propensity for side effects and that
anti-psychotics are still commonly prescribed to people
with dementia, contrary to clinical guidelines. Similarly,
Hungerford et al. [36] reported that only a small proportion
of clients living in a major urban area of Australia who had
been referred for Dementia Behaviour Management
Advisory Services (DBMAS) had a psychotic co-morbid-
ity, but almost one-quarter had been prescribed antipsy-
chotic medicines.
While management of BPSD through the use of psy-
chotropic medicine is acknowledged as prevalent in resi-
dential care facilities [12–14], there is little recognition of
management of these behaviours in the community setting
and the impact it has on caregivers. Similarly, acknowl-
edgement is increasing of the need to implement educa-
tional support programmes for care workers in residential
care facilities in terms of inappropriate use of psychotropic
medicines and strategies to improve communication with
residents [37]; however, there has been little discussion in
this regard in the community setting.
4.1 Limitations
Due to resourcing constraints, we did not examine docu-
mentation for the duration of treatment, psychotropic
interactions or possible adverse effects associated with the
use of psychotropic medicines, whether there were multiple
prescribers or the development of care plans for all of our
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study population and thus we are not able to comment on
these. The MMSE score in our population was part of a
home nursing service assessment and not a general prac-
titioner or geriatrician assessment; therefore, we cannot
make inferences with regard to its use in the prescribing of
cholinesterase inhibitors. Additionally, as the MMSE was
not consistently performed, we cannot make inferences
with regard to the severity of dementia/cognitive
impairment.
5 Conclusion
Cholinesterase inhibitor dosage exceeded the therapeutic
range, and in many cases no formal diagnosis of Alzhei-
mer’s disease was recorded among those prescribed this
medication. Antidepressants were used by more than dou-
ble the number of people who were documented as having
a history of depression or anxiety disorders. Antipsychotic
medicines appear to have been more frequently prescribed
for BPSD or an undocumented purpose than to treat
schizophrenia or affective bi-polar disorder. Additionally,
risperidone—the most commonly prescribed antipsy-
chotic—was in some cases prescribed above levels that
achieve maximum response in people with dementia and
who had no documented diagnosis of schizophrenia, and
multiple benzodiazepines were prescribed despite no evi-
dence that use of more than one benzodiazepine is
beneficial.
We believe that, to date, our study is the first to
undertake an investigation into the use of psychotropic
medicines by people living in the Australian community
with a cognitive impairment. As such, our findings provide
an opportunity for quality improvement. While further
research is needed into the extent of psychotropic medici-
nes in the wider community setting, we believe we have
found sufficient evidence to make the following
conclusions:
• There is a need to continue to raise awareness of the
risks of adverse outcomes associated with the use of
psychotropic medicines in older people.
• There is a need for the implementation of support
programmes that include education on appropriate
behavioural interventions for those who support people
with dementia, Alzheimer’s disease, short-term mem-
ory loss and cognitive impairment.
• There is a need for regular review of medicines for this
group to ensure quality use of medicines for older
people with dementia living in the community.
• There is a need for improved documentation by health
professionals on the recording of diagnoses and the
indications for the prescribing of psychotropic
medicines.
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